相似文献
1
cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease.
J Neurosci. 1999 Sep 1;19(17):7486-94. doi: 10.1523/JNEUROSCI.19-17-07486.1999.
2
Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.
Eur J Biochem. 1998 Mar 15;252(3):542-52. doi: 10.1046/j.1432-1327.1998.2520542.x.
3
Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain.
J Neurochem. 1994 Oct;63(4):1416-25. doi: 10.1046/j.1471-4159.1994.63041416.x.
4
PKA phosphorylations on tau: developmental studies in the mouse.
Dev Neurosci. 2000;22(4):303-9. doi: 10.1159/000017454.
5
Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3beta and PKA kinase activities.
FEBS Lett. 2002 Apr 10;516(1-3):151-5. doi: 10.1016/s0014-5793(02)02525-5.
6
Tau therapeutic strategies for the treatment of Alzheimer's disease.
Curr Top Med Chem. 2006;6(6):579-95. doi: 10.2174/156802606776743057.
7
Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356.
Biochem J. 1996 Jun 1;316 ( Pt 2)(Pt 2):655-60. doi: 10.1042/bj3160655.
8
In situ hybridization of calcium/calmodulin dependent protein kinase II and tau mRNAs; species differences and relative preservation in Alzheimer's disease.
Brain Res Mol Brain Res. 1992 Jan;12(1-3):85-94. doi: 10.1016/0169-328x(92)90071-i.
9
A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
Brain Res. 1999 Feb 13;818(2):383-96. doi: 10.1016/s0006-8993(98)01307-9.
10
Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.
Brain Res. 1998 Jun 29;797(2):267-77. doi: 10.1016/s0006-8993(98)00296-0.
引用本文的文献
1
Novel Pathological Mechanisms Revealed by Spatial Transcriptomic Analysis of Hippocampus in Aged Control, Primary Age-Related Tauopathy, and Alzheimer's Disease.
Res Sq. 2025 Aug 22:rs.3.rs-7303622. doi: 10.21203/rs.3.rs-7303622/v1.
2
Newly Identified Genetic Associations of Alzheimer Disease by Conditional Selective Inference: Potential Implications for the Tau Hypothesis.
Bioinform Biol Insights. 2025 Aug 17;19:11779322251358309. doi: 10.1177/11779322251358309. eCollection 2025.
3
Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration in males in a mouse model of tauopathy.
Nat Neurosci. 2025 May 27. doi: 10.1038/s41593-025-01966-7.
4
The Unified Theory of Neurodegeneration Pathogenesis Based on Axon Deamidation.
Int J Mol Sci. 2025 Apr 27;26(9):4143. doi: 10.3390/ijms26094143.
5
Vulnerability of the entorhinal cortex II to neurodegeneration in Alzheimer's disease.
Brain Commun. 2025 Feb 26;7(2):fcaf091. doi: 10.1093/braincomms/fcaf091. eCollection 2025.
6
Activity of Protein Kinase A in the Frontal Cortex in Schizophrenia.
Brain Sci. 2023 Dec 22;14(1):13. doi: 10.3390/brainsci14010013.
7
Assessing individual variability of the entorhinal subfields in health and disease.
J Comp Neurol. 2023 Dec;531(18):2062-2079. doi: 10.1002/cne.25538. Epub 2023 Sep 12.
8
The Expression of Epac2 and GluA3 in an Alzheimer's Disease Experimental Model and Postmortem Patient Samples.
Biomedicines. 2023 Jul 25;11(8):2096. doi: 10.3390/biomedicines11082096.
9
The old second messenger cAMP teams up with novel cell death mechanisms: potential translational therapeutical benefit for Alzheimer's disease and Parkinson's disease.
Front Physiol. 2023 Jun 19;14:1207280. doi: 10.3389/fphys.2023.1207280. eCollection 2023.
10
Alzheimer's Disease: Significant Benefit from the Yeast-Based Models.
Int J Mol Sci. 2023 Jun 6;24(12):9791. doi: 10.3390/ijms24129791.
本文引用的文献
1
Hierarchical phosphorylation of recombinant tau by the paired-helical filament-associated protein kinase is dependent on cyclic AMP-dependent protein kinase.
J Neurochem. 1999 Jan;72(1):214-24. doi: 10.1046/j.1471-4159.1999.0720214.x.
2
New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.
J Neurochem. 1998 Dec;71(6):2465-76. doi: 10.1046/j.1471-4159.1998.71062465.x.
3
The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.
Mol Biol Cell. 1998 Jun;9(6):1495-512. doi: 10.1091/mbc.9.6.1495.
4
A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease.
J Neurochem. 1997 Nov;69(5):2087-95. doi: 10.1046/j.1471-4159.1997.69052087.x.
5
Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites.
Biochemistry. 1997 Jul 1;36(26):8114-24. doi: 10.1021/bi970380+.
6
Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau.
J Neurosci Res. 1997 Apr 15;48(2):128-32. doi: 10.1002/(sici)1097-4547(19970415)48:2<128::aid-jnr5>3.0.co;2-e.
7
Conversion of serine to aspartate imitates phosphorylation-induced changes in the structure and function of microtubule-associated protein tau.
J Biol Chem. 1997 Mar 28;272(13):8441-6. doi: 10.1074/jbc.272.13.8441.
8
Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein.
FEBS Lett. 1996 Apr 8;384(1):25-30. doi: 10.1016/0014-5793(96)00271-2.
9
Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein.
Science. 1996 Mar 15;271(5255):1589-92. doi: 10.1126/science.271.5255.1589.
10
Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases.
FASEB J. 1995 Dec;9(15):1570-6. doi: 10.1096/fasebj.9.15.8529836.
Zotero 插件